已发表论文

miRNAs 在胰腺导管腺癌诊断、化疗耐药和预后中的作用

 

Authors Ren L, Yu Y

Received 16 October 2017

Accepted for publication 18 December 2017

Published 25 January 2018 Volume 2018:14 Pages 179—187

DOI https://doi.org/10.2147/TCRM.S154226

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Hoa Le

Peer reviewer comments 3

Editor who approved publication: Professor Deyun Wang

Abstract: Pancreatic ductal adenocarcinoma (PDAC) remains a very challenging malignancy with late presentation, metastatic potential, chemoresistance, and poor prognosis. Therefore, there is an urgent need for novel diagnostic and prognostic biomarkers. miRNAs are small noncoding RNAs that regulate the expression of multitude number of genes. Aberrant expression of miRNAs has been linked to the development of various malignancies, including PDAC. A series of miRNAs have been defined as holding promise for early diagnostics, as indicators of therapy resistance, and even as markers for prognosis in PDAC patients. In this review, we summarize the current knowledge on the role of miRNAs in diagnosis, chemoresistance, and prognosis in PDAC patients.
Keywords: pancreatic ductal adenocarcinoma, miRNA, diagnosis, prognosis, chemoresistance